Ganoderma lucidum polysaccharides ameliorate lipopolysaccharide-induced acute pneumonia via inhibiting NRP1-mediated inflammation

Pharm Biol. 2022 Dec;60(1):2201-2209. doi: 10.1080/13880209.2022.2142615.

Abstract

Context: Ganoderma lucidum polysaccharides (GLP), from Ganoderma lucidum (Leyss. ex Fr.) Karst. (Ganodermataceae), are reported to have anti-inflammatory effects, including anti-neuroinflammation and anti-colitis. Nevertheless, the role of GLP in acute pneumonia is unknown.

Objective: To explore the protective role of GLP against LPS-induced acute pneumonia and investigate possible mechanisms.

Materials and methods: GLP were extracted and used for high-performance liquid chromatography (HPLC) analysis after acid hydrolysis and PMP derivatization. Sixty C57BL/6N male mice were randomly divided into six groups: Sham, Model, LPS + GLP (25, 50 and 100 mg/kg/d administered intragastrically for two weeks) and LPS + dexamethasone (6 mg/kg/d injected intraperitoneally for one week). Acute pneumonia mouse models were established by intratracheal injection of LPS. Haematoxylin and eosin (H&E) staining was examined to evaluate lung lesions. ELISA and quantitative real-time PCR were employed to assess inflammatory factors expression. Western blots were carried out to measure Neuropilin-1 expression and proteins related to apoptosis and autophagy.

Results: GLP suppressed inflammatory cell infiltration. In BALF, cell counts were 1.1 × 106 (model) and 7.1 × 105 (100 mg/kg). Release of GM-CSF and IL-6 was reduced with GLP (25, 50 and 100 mg/kg) treatment. The expression of genes IL-1β, IL-6, TNF-α and Saa3 was reduced. GLP treatment also suppressed the activation of Neuropilin-1 (NRP1), upregulated the levels of Bcl2/Bax and LC3 and led to downregulation of the ratio C-Caspase 3/Caspase 3 and P62 expression.

Discussion and conclusions: GLP could protect against LPS-induced acute pneumonia through multiple mechanisms: blocking the infiltration of inflammatory cells, inhibiting cytokine secretion, suppressing NRP1 activation and regulating pneumonocyte apoptosis and autophagy.

Keywords: COVID-19; Ganodermataceae; anti-inflammatory; pneumonocyte apoptosis.

Publication types

  • Randomized Controlled Trial, Veterinary

MeSH terms

  • Animals
  • Caspase 3
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Interleukin-6 / metabolism
  • Lipopolysaccharides / toxicity
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuropilin-1
  • Pneumonia* / chemically induced
  • Pneumonia* / drug therapy
  • Pneumonia* / prevention & control
  • Polysaccharides / pharmacology
  • Reishi* / chemistry

Substances

  • Caspase 3
  • Interleukin-6
  • Lipopolysaccharides
  • Neuropilin-1
  • Polysaccharides

Grants and funding

This study was financially supported by the National Key Research and Development Plan Program under Grant [number 2019YFC1710504] and CAMS Innovation Fund for Medical Sciences (CIFMS) Grant [number 2021-I2M-1-031].